MUC1 and cancer: Since the first pioneered candidate AS1402 failed in a phase II clinical study because of its cancer-promoting effect [24], alternative approaches such as drug-conjugates, peptides, or vaccines have been investigated, but few have used MUC1-C*-targeting monoclonal antibodies.